New Challenges and Advances in the Treatment of Lung Cancer: From Predictive Biomarkers to Minimally Invasive Techniques
A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Thoracic Oncology".
Deadline for manuscript submissions: closed (15 January 2025) | Viewed by 1204
Special Issue Editors
Interests: thoracic surgery
Interests: experimental surgery; gastrointestinal cancer; breast cancer; lung cancer; transplantation; gastrointestinal surgery; general surgery
Special Issue Information
Dear Colleagues,
Lung cancer is the leading cause of cancer-related death, with non-small-cell (NSCLC) coming out on top according to the 2020 global cancer statistics; this type represents 80–85% of all lung cancers globally. Despite advances in treatment, the five-year survival rate for NSCLC patients is below 18%, primarily because about 70% of patients present with advanced disease at diagnosis. The treatment of patients with lung cancer includes multidisciplinary approaches that are based on surgical practice, such as chemotherapy, radiotherapy, targeted therapies, and immunotherapy, which largely improve quality of life and survival rates.
We invite potential contributors to submit their work on the current challenges in lung cancer and the newest advances in, as well as updated role of, minimally invasive techniques. In particular, are interested in survival predictors, including the newest neoadjuvant chemoradiation regimens. Original articles, narrative reviews, and systematic reviews will be considered for publication.
We look forward to receiving your contributions.
Dr. Efstratios Koletsis
Prof. Dr. Alexandra Tsaroucha
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- lung cancer
- immunotherapy
- lung disease
- targeted therapy
- video-assisted thoracoscopic surgery (VATS)
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
